Journal of Leukocyte Biology Myeloid cells, immune suppression, tumor immunology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sartor, L.
Right arrow Articles by Garbisa, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sartor, L.
Right arrow Articles by Garbisa, S.
(Journal of Leukocyte Biology. 2002;71:73-79.)
© 2002 by Society for Leukocyte Biology

(-)Epigallocatechin-3-gallate inhibits leukocyte elastase: potential of the phyto-factor in hindering inflammation, emphysema, and invasion

Luigi Sartor, Elga Pezzato and Spiridione Garbisa

Department of Experimental Biomedical Sciences, Medical School of Padova, Italy

Correspondence: Prof. Spiridione Garbisa, Dept. Experimental Biomedical Sciences, Medical School of Padova, viale G.Colombo 3, 35121 Padova, Italy. E-mail: garbisa{at}unipd.it


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Flavanol (-)epigallocatechin-3-gallate is shown to be a potent natural inhibitor of leukocyte elastase that may be used to reduce elastase-mediated progression to emphysema and tumor invasion. This phyto-factor, abundant in green tea, exerts a dose-dependent, noncompetitive inhibition of leukocyte elastase at a noncytotoxic concentration and is effective in neutrophil culture. This inhibition shows an IC50 of 0.4 µM, 30 times higher than the {alpha}1-protease inhibitor but lower than other known natural and synthetic elastase inhibitors. The flavanol inhibits leukocyte elastase at concentrations of 50, 150, and 2500 times lower than that effective on gelatinases (MMP-2 and MMP-9), thrombin, and cathepsin G, respectively, and also blocks elastase-mediated activation of MMP-9.

Key Words: proteinases • neutrophils • connective tissue • inhibition


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Some inflammatory diseases, including cystic fibrosis, glomerulo-nephritis, rheumatoid arthritis, chronic obstructive pulmonary disease, and emphysema, register a progressive modification of tissue architecture, eventually impairing organ function. In these cases, serine- and metallo-proteinases have been shown to be instrumental in extracellular matrix alteration [1 ]. Among the serine-proteinases, the elastase, mainly released upon stimulation by neutrophil leukocytes (LE) at a site of inflammation, has the potential to preferentially disrupt the elastic network, although natural substrates of LE also include collagens I–IV, other extracellular matrix and circulating molecules, and bacterial cell walls. In addition, LE can activate a number of matrix metalloproteinases (MMPs) and inactivate their tissue inhibitors [2 ].

This enzyme is physiologically counterbalanced by endogenous serine-proteinase inhibitors—{alpha}1-proteinase inhibitor ({alpha}1-PI; also known as {alpha}1-antitrypsin), {alpha}2-macroglobulin, and secretory leukoproteinase inhibitor [3 ]—but any enzyme/inhibitor imbalance may lead directly to increased lysis of extracellular matrix macromolecules and increased risk of tissue injury in the immediate vicinity of activated neutrophils [4 ]. In particular, {alpha}1-PI deficiency is the most prevalent, potentially fatal hereditary disease in white individuals and is an important risk factor for pulmonary emphysema [5 ]. However, elastase burden may also be increased as a result of increased recruitment of leukocytes to the lung, sustained by viral or bacterial pathogens encouraged by environmental conditions or life habits. There may also be a functional deficiency of inhibitor(s) as a result of inactivation in the lung by oxidation (from cigarette smoke or oxygen radicals released from inflammatory leukocytes) [6 ].

As for treatment, in many cases of airway inflammation, exogenous elastase inhibitors would be first-choice drugs, and direct {alpha}1-PI replacement is one potential therapeutic approach currently under investigation. Several heterocyclic inhibitors quite specific for LE have been developed, with constant (Ki) values in the range of 10-5–10-7 M [7 ]. Peptide chloromethyl ketones are also effective inhibitors in animal models of emphysema and have served as a standard of comparison for newly developed inhibitors but present side effects that make them unsuitable for human therapeutic use [8 ]. Conversely, good inhibition of metalloproteinases has been demonstrated for noncytotoxic concentrations of some natural polyphenol compounds. One abundant source is green tea [9 ], whose polyphenols are mainly flavanols or "catechins." In this beverage, epigallocatechin-3-gallate (EGCG) is the most prevalent, followed by epigallocatechin (EGC); after moderate green tea consumption, its plasma concentration reaches 0.1–0.3 µM [10 ]. Recent in vivo experiments show that these levels are sufficient to lower body- and liver-fat accumulation [11 ] and inhibit angiogenesis [12 ] and tumor-cell invasive aggressiveness in vitro [13 14 15 16 ]. In particular, EGCG is a direct inhibitor of MMP-2 and MMP-9, the two gelatinases most frequently overexpressed in cancer and angiogenesis, instrumental in cutting through basement membrane barriers [17 18 19 ] and degrading extracellular matrix proteins in human pulmonary emphysema [20 ].

This study shows that the most abundant flavanol of green tea exerts a potent inhibitory effect on human LE but also restrains thrombin activity. LE inhibition takes place at a concentration much lower than that shown on gelatinases [17 ] and urokinase-type plasminogen activator (uPA) [21 ], far from cytotoxicity, in the range of some potent synthetic LE inhibitors [7 ], and lower than that of some commonly used serine-proteinase inhibitors. The results from biochemical and biological assays strongly suggest the pharmacological use of EGCG in the prevention and containment of LE-mediated pathologies.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Reagents
Elastase and cathepsin G from human leukocytes, porcine pancreatic elastase, elastase substrate N-methoxysuccinyl-ala-ala-pro-val p-nitroanilide, EGCG, EGC, all the inhibitors, cytochalasin B, and formyl-Met-Leu-Phe (fMLP) were purchased from Sigma Chemical Co. (St. Louis, MO). Thrombin from human plasma, cathepsin G substrate suc-ala-ala-pro-phe-pNA, and thrombin substrate H-sar-pro-arg-pNA were obtained from Calbiochem-Novabiochem (Nottingham, UK). Human k-elastin was obtained as already described [22 ].

Substrate degradation by serine-proteinases
Leukocyte and pancreatic elastases, cathepsin G, and thrombin were solubilized (250 mU/ml) in Hepes buffer [0.1 M Hepes, 0.5 M NaCl, 10% dimethyl sulfoxide (DMSO)] at pH 8.0 (elastase and thrombin) and 7.5 (cathepsin G). All the inhibitors were freshly prepared 5x in the same buffers, except phenylmethylsulfonyl fluoride (PMSF; 10x), for which 10% ethanol was added. Elastase substrate was prepared (20x) in 100% ethanol, and cathepsin substrate was prepared (20x) in 100% DMSO. Dilutions of the inhibitor were premixed with the enzymes in micrometer wells and maintained for 15 min at 4°C; 5 µl specific substrate at various concentrations (10–500 µM) was then added to 100 µl final volume, and the mixture was incubated at 37°C. At 20–30-min intervals, the intensity of the color developed by digested substrate was measured at 405 nm with a Titertek Multiskan (Flow Laboratories, McLean, VA), and the control background was subtracted. Logarithmic plot and double-reciprocal plot of the results allowed the IC50s and the type and Ki of inhibition exerted on LE by EGCG to be deduced.

Elastin-zymography and gelatin-zymography [23 ] were also used to confirm the inhibition of LE and thrombin by EGCG. Without heating, 10 mU LE and 100 mU thrombin were electrophoresed in 0.15% k-elastin- and 0.1% gelatin-containing 10% polyacrylamide, respectively. The gel was then washed twice for 15 min with 2.5% Triton X-100; cut into slices corresponding to the lanes and then put in different tanks containing the stated concentrations of EGCG; incubated for 72 h at 37°C in Hepes-buffer (as above); stained for 30 min with 30% methanol/10% acetic acid containing 0.5% Coomassie brilliant blue R-250; and destained in the same solution without dye. Clear bands represent areas of gelatinolysis on the blue background.

Elastase-mediated gelatinase activation
Serum-less HT1080 human fibrosarcoma cell-conditioned medium was used as a source of gelatinases, being pro-MMP-9 the prevalent type. LE and EGCG were diluted in Hepes buffer to 1 mU/µl and 25 µM, respectively, and then 5 µl LE was mixed with 18 µl flavanol solution at 4°C. After 15 min, 150 µl medium was added, and the volumes adjusted to 180 µl. Following 4 h incubation at 37°C, 60 µl sodium dodecyl sulfate (SDS)-electrophoresis buffer 4x was added, and after mixing, 1/10 of the volume (24 µl) was processed for gelatin-zymography (6% polyacrylamide), which was developed overnight in Tris-buffer (50 mM Tris-HCl, 200 mM NaCl, 10 mM CaCl2, pH 7.4) and stained as above.

Neutrophil isolation and elastolytic activity
Neutrophils were isolated under endotoxin-free conditions from buffy-coats of healthy donors, according to a single-step separation procedure [23 ], as previously described in detail [24 ]. The resulting cell population contained 96–98% neutrophils with traces of eosinophils and mononuclear cells.

The cells were suspended in phenol red-less DME/F12 (Sigma-Aldrich, St. Louis, MO), mixed 1:1 with Hepes buffer containing µM concentration of inhibitor, directly seeded (2.5x105 cells/200 µl) onto plastic microwells and incubated at 37°C in 5% CO2 in air. After 15 min, 5 µg/ml cytochalasin B was added, followed after 5 min by 100 nM fMLP [23 ]. The elastase substrate was then added at 0.5 mM final concentration, and the absorbance was measured at 405 nm, as above, at 20–30-min intervals up to 2 h.

The inhibition of elastolytic activity was also tested in medium conditioned 6 h by the same number of neutrophils, incubated with 0.5 mM substrate ± 5 µM inhibitor. The lysis of the substrate was measured as above, and the inhibition referred as percent of control after 2 h.

Western blotting
Samples of medium conditioned by an equal number of neutrophils ± 5 µM EGCG were electrophoresed in 10% polyacrylamide gel in SDS and electroblotted to a Hybond-C Extra nitrocellulose membrane (Amersham Pharmacia Biotech, Little Chalfont, UK). The Western blotting was developed by standard procedure using rabbit anti-human neutrophil elastase or cathepsin G antibody 1:200 (Inalco, Milano, Italy) and horseradish peroxidase-labeled anti-rabbit immunoglobulin G (IgG) 1:1500 (Sigma Chemical Co.). Antigen detection was achieved by incubating the membrane for 1 min at room temperature with 0.125 ml/cm2 enhanced chemiluminescence (ECL)-detection solution and exposing it to Hyperfilm MP (both from Amersham Pharmacia Biotech).

Neutrophil-promoted pro-MMP-9 activation
Neutrophils (5x105 in 200 µl Dulbecco’s modified Eagle’s medium) were seeded onto plastic microwells, activated by cytochalasin-fMLP as above, and incubated at 37°C in 5% CO2 in air with or without 5 µM EGCG. After 6 h, 30 µl aliquots of the conditioned medium were clarified and processed directly for gelatin-zymography.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
EGCG inhibits degradation of synthetic substrate by human LE
To assay the inhibition exerted on human LE by EGCG and EGC, 5 mU purified LE was incubated for up to 2 h with the two flavanols in the presence of increasing concentrations of its synthetic substrate (N-methoxysuccinyl-ala-ala-pro-val p-nitroanilide). Within the 0.1–0.5 mM range of substrate, LE activity is strongly inhibited by 1 µM EGCG but affected very little by 1 µM EGC (Fig. 1 a ), and no synergistic effect was registered (unpublished results). The inhibition exerted by EGCG is dose-dependent and noncompetitive, as determined by double-reciprocal plotting of the results obtained at different flavanol concentrations (Fig. 1b) ; the plots share a common -1/Michaelis constant (Km) on the abscissa, and the calculated Ki is 0.34 µM.



View larger version (17K):
[in this window]
[in a new window]
 
Figure 1. LE activity in the presence of flavanols. (a) Inhibition of enzymatic activity (5 mU) by 1 µM flavanols EGCG and EGC compared with control (•) on increasing concentration of synthetic substrate. (b) Double-reciprocal plot demonstrating noncompetitive inhibition of LE (5 mU) by increasing concentration of EGCG (S=substrate). Examples of triplicate experiments, analyzed at 60 min; the points represent the mean values of three wells, with SD < 10%.

 
When 5 mU LE was incubated with elastase substrate in the presence of 1 µM inhibitor, the degradation was reduced 65% by EGCG and completely blocked by {alpha}1-PI, whereas ovomucoid, aprotinin, and PMSF lacked any effect (unpublished results). The inhibition by EGCG was maintained with a constant slope throughout the 2 h of measurement (unpublished results), and the deduced IC50 was 0.4 µM. This concentration is approximately 50-fold lower (Fig. 2 ) than that shown for MMP-2 and MMP-9 by our group [19 ] and 10,000 that shown for uPA by others [21 ]. Under the same conditions, we deduced a 30-fold lower IC50 for {alpha}1-PI (13 nM) but much higher values for aprotinin (0.2 mM), PMSF (0.4 mM), and ovomucoid (4 mM). The inhibition of LE was also verified by k-elastin-zymography, developed in the presence of increasing concentrations of EGCG; dose-dependent inhibition of in situ degradation of k-elastin by 50 mU LE was indeed evident within 0.1–2 µM flavanol (unpublished results).



View larger version (14K):
[in this window]
[in a new window]
 
Figure 2. EGCG IC50 for LE, cathepsin G, and thrombin activity on synthetic substrates. Dose-response inhibition by the flavanol of LE, cathepsin G, and thrombin (examples of triplicate experiment, points average of triplicate digestions, SD<10%) compared with gelatinase MMP-2 (redrawn from ref. [17 ]) and uPA (redrawn from ref. [21 ]).

 
In contrast, when human thrombin (50 mU) and cathepsin G (5 mU) were incubated with their specific synthetic substrate (500 µM and 100 µM) in the presence of increasing amounts of EGCG, the deduced IC50 was 60 µM and 1 mM, respectively (Fig. 2) . Furthermore, no inhibition of porcine pancreatic elastase was obtained using EGCG up to 1 mM (unpublished results). The inhibition of thrombin activity was also verified by gelatin-zymography developed in the presence of increasing concentrations of EGCG; dose-dependent inhibition of in situ degradation of gelatin by 100 mU thrombin was indeed evident within 10–103 µM flavanol (unpublished results).

EGCG inhibits degradation of LE substrate by neutrophils
When freshly isolated human peripheral blood neutrophils (2.5x105), shortly preincubated with increasing concentrations of EGCG (0.3–9 µM), were activated with cytochalasin B-fMLP, the degradation of elastase substrate (500 µM) was inhibited in a dose-dependent manner (Fig. 3 a ). This was revealed by the increased absorbance at 405 nm as a result of the release of colored digestion products. Almost 30% inhibition was measured within the first 45 min with 9 µM EGCG, after which the effect decreased progressively during the following 60 min at all concentrations.



View larger version (28K):
[in this window]
[in a new window]
 
Figure 3. Inhibition of elastase synthetic substrate degradation by human neutrophils. (a) Freshly isolated neutrophils (2.5x105) were incubated in microwells in the presence of 0.5 mM substrate and increasing concentration of EGCG (0.3–9 µM). (b) Neutrophils (as above) were incubated for 1 h in the presence of 5 µM inhibitor; the inhibition of elastolytic activity is expressed as percent of that exerted by EGCG. (c) The medium conditioned for 6 h by control neutrophils (2.5x105) was incubated with 0.5 mM substrate in the presence of 5 µM inhibitor. The inhibition is referred to as percent of degradation in the control after 2 h. (a–c) Lysis of the substrate was monitored by measuring the absorbance at 405 nm; the bars represent the mean values of three wells, with SD < 10%. Examples of duplicate experiment.

 
To directly compare in culture the effect of EGCG and other cell-compatible proteinase inhibitors, 2.5 x 105 activated neutrophils were also incubated up to 1 h with elastase substrate in the presence of the same concentration (5 µM) of EGCG, aprotinin, 1–10 phenanthroline, or pepstatin A. Aprotinin developed approximately 30% of the inhibition exerted by EGCG, 1–10 phenanthroline <5%, and pepstatin A <10%, as confirmed in duplicate experiments (example in Fig. 3b ).

The inhibition by other standard class-specific proteinase inhibitors was also tested in the cell-free system, on culture medium conditioned for 6 h by freshly isolated neutrophils and incubated up to 2 h with elastase substrate. While 5 µM EGCG reduced up to 67% of the substrate degradation measured in the control, this was almost completely suppressed by the same concentration of {alpha}1-PI but only <15% and <5% by 10 mM ethylenediaminetetraacetate (EDTA) and N-ethylmaleimide (NEM), respectively, in duplicate experiments (Fig. 3c) .

EGCG inhibits MMP-9 activation by purified LE and isolated neutrophils
The possibility that EGCG may interfere with LE activation of MMPs [2 ], in particular with gelatinases MMP-2 and MMP-9, was also analyzed. When culture medium containing mostly pro-MMP-9 was incubated for 4 h with 0.5 mU LE before assaying in gelatin-zymography, the conversion of the zymogen to the activated form of MMP-9 was restrained substantially by the presence of 2.5 µM EGCG (Fig. 4 a ) but not EGC (unpublished results). Under the same conditions, LE alone did not produce substantial increments of the MMP-2 activated form.



View larger version (58K):
[in this window]
[in a new window]
 
Figure 4. EGCG inhibits activation of pro-MMP-9. Gelatin-zymography of (a) equal volumes of MMP-9 gelatinase-containing culture medium preincubated for 4 h at 37°C with 0.5 mU LE ± 2.5 µM EGCG, and (b) culture medium conditioned for 6 h at 37°C by equal number of neutrophils ± 5 µM EGCG. The conversion of pro-MMP-9 (p) to the activated form (a) is promoted by LE and neutrophils; this conversion is restrained by EGCG. (c) Western blotting for LE in equal amount of medium conditioned by neutrophils as above. LE is already fully expressed after 1 h, and its secretion is not appreciably modified by EGCG.

 
Parallel results were obtained when freshly isolated neutrophils were incubated for 6 h in the presence of 5 µM flavanol. Gelatin-zymography of the culture medium shows abundant MMP-9, as already demonstrated [25 ], most in the zymogen form, plus an unidentified gelatinolytic band of lower relative mobility (Mr). Although already less represented in the control, the activated form of MMP-9 was diminished substantially in the presence of EGCG (Fig. 4b) . The level of total secreted MMP-9 registered no substantial difference. EGC had no effect (unpublished results).

EGCG does not reduce elastase and cathepsin G secretion by neutrophils
To verify whether EGCG restrains LE and cathepsin G secretion, 106 freshly isolated neutrophils were preincubated in serum-less medium with and without 5 µM flavanol and activated with cytochalasin A-fMLP as above; then the conditioned medium was analyzed directly at 1, 2, and 4 h by Western blotting for the two serine-proteinases. The presence of the flavanol had no measurable effect on the level of LE (Fig. 4c) or cathepsin G (unpublished results) released into the culture medium, which remained constant from 1 h onward.


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Readily achievable plasma concentrations [10 ] of the major flavanol of green tea, EGCG, inhibit the activity of human LE in a dose-dependent, noncompetitive manner, with Ki below 350 nM. As determined from the IC50s in the experimental conditions used, this phyto-component is only 30x less potent than {alpha}1-PI, the endogenous inhibitor most involved in balancing elastolytic burst in inflamed lungs [4 , 5 ]. Conversely, EGCG exerts an inhibition superior to a variety of natural and synthetic inhibitors: its IC50 is 1/40 that shown for the microbial elastase-like proteinase inhibitor elastinal [26 ] and between 1/50 and 1/200 that of some substituted cephalosporines, ß-lactams and trifluoro-methyl ketones—the latter ones recently suggested for the treatment of diseases characterized by neutrophil and LE involvement [27 ]. The inhibition is much superior to that exerted by some standard class-specific, serine-proteinase inhibitors ovomucoid, aprotinin, and PMSF which also exert moderate activity on LE [28 , 29 ], and is maintained by EGCG over the 2-h period of measurement with a constant slope, suggesting a durable EGCG effect at body temperature.

EGCG is also effective on neutrophil culture. In fact, noncytotoxic concentrations of flavanol restrain the elastolytic activity of freshly isolated neutrophils in a dose-dependent manner, although less efficiently compared with the biochemical assays. At any concentration of flavanol, the inhibition of neutrophil elastolytic activity declines progressively over the first 2 h of incubation, although we verified that LE is released into the medium only during the initial phase following activation. The constant slope of the time-course inhibition registered with purified LE should rule out the possibility that this decline may be attributable to the thermo-instability of the flavanol. Most likely, the loss of EGCG potential may be attributable to flavanol oxidation by the hydrogen peroxide secreted after a lag period during a prolonged respiratory burst induced on neutrophils by cytochalasin-fMLP treatment [30 ].

Under the same conditions, aprotinin is 70% less effective in comparison with the same concentration of flavanol; this moderate effect is not in conflict with the complete lack of inhibition of LE in the test tube, because it may be a result of a block of other serine-proteinases active on the substrate. Certainly, most of the elastolytic activity released by the neutrophils is attributable to serine-proteinases as inferred from the complete inhibition of substrate degradation in the presence of {alpha}1-PI and the marginal inhibition in the presence of metallo-proteinase (1.10 phenanthroline, EDTA) and cysteine-proteinase inhibitors (pepstatin A, NEM). Furthermore, because of the two serine-proteinases released mostly by neutrophils, cathepsin G is, in comparison, largely insensitive to EGCG (see below), the prevalent serine-proteinase inhibited by µM flavanol should be LE. Indeed, the presence of LE into the medium was proved by specific antibodies, which revealed unmodified levels of the proteinase in the presence of the flavanol. Conversely, the abundant MMP-9 secreted by neutrophils may be, in part, responsible for the elastolytic metallo-proteinase activity (see below).

Regardless of the respective contribution in elastin degradation, MMP-9 and LE are extracellularly blocked by the flavanol, which thus has the potential to contain the degradative neutrophil activity in an in vivo context in the case of endogenous inhibitor failure. In fact, EGCG has already been shown to inhibit two gelatinases, MMP-2 and MMP-9 [17 18 19 ], whose activity is instrumental to endothelial and tumor cells in cutting through extracellular matrix barriers during angiogenetic and invasive/metastatic processes and pulmonary emphysema [20 ]. We showed that the IC50 of EGCG for these MMPs lies in the range of 10–30 µM [19 ], and the second-most abundant flavanol in green tea, EGC, shows much lower efficacy (1/30). Biochemical assays now reveal that EGCG exerts an even stronger inhibition of LE (50x). This inhibition occurs at concentrations approximately 25-fold and two orders of magnitude lower than the cytotoxic threshold already demonstrated on transformed and normal endothelial cells, respectively [19 ], and similar to those in the plasma of moderate green tea drinkers (0.1–0.3 µM) [10 ]. Again, EGC exerts very little inhibition.

Also, cathepsin G, stored in the azurophilic granules of neutrophils and monocytes and released upon cell stimulation or lysis, can degrade a wide array of matrix and humoral proteins, although less potently than LE [2 ], and activate MMP-9 [31 ]. While cathepsin G release is not affected by µM concentrations of EGCG, the inhibition exerted by the flavanol on its activity is markedly weaker than that on LE (1/2500) but also less pronounced than that on MMP-2 (1/50): the IC50 on cathepsin G is in the mM range, close to that on uPA [21 ], and may contribute to the residual MMP-9 activation at EGCG concentrations over one order of magnitude of the IC50 for LE (see below). The differential effectiveness of EGCG on the activity of LE and cathepsin G may prove to be useful in clinical application of the flavanol, considering the need to preserve a number of cathepsin G-mediated reactions (i.e., coagulation, immune response, and wound debridement) [2 ].

When purified LE is incubated with pro-MMP-9 in a cell-free system, the conversion of this zymogen into activated form is restrained substantially in the presence of EGCG. In addition, the activation of pro-MMP-9 secreted by freshly isolated neutrophils is somewhat limited when they are cultured briefly in the presence of the flavanol. This reduced activation may play an important role in airway inflammation and tumor disease; it would contribute to the down-regulation of local proinflammatory interleukin (IL)-1ß activity [32 ], restraint of transforming growth factor-ß (TGF-ß) induction of tumor-cell invasion and angiogenesis [33 ], preservation of the most potent inhibitor of LE [34 ], restraint of neutrophil recruitment by chemoattractant fragments of {alpha}1-PI [35 ], preservation of the underlying elastin structure of the lung [20 , 36 ], and containment of degradation of the basement membrane molecular scaffold, a prerequisite for angiogenesis [12 ] and tumor-cell invasion.

Regarding angiogenesis, elastase has been shown to convert plasminogen into angiostatin [37 ], a potent inhibitor of angiogenesis, and elastase activity inhibition by EGCG could inhibit production of angiostatin, thus promoting inflammation. This paradox may be only apparent; in fact, angiostatin is only one of the endogenous inhibitors of angiogenesis (e.g., endostatin and thrombospondin), and inhibition of LE and inflammation reduces the expression of a number of proangiogenic factors [i.e., fibroblast growth factor (FGF)-ß, platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and cytokines).

Regarding tumor-cell invasion, the inhibition of direct lytic activity of LE on collagen IV [2 ] must also be taken into account as a potential contributor to the documented reduction of tumor-invasive processes [9 , 13 ]. Conversely, the level of MMP-9 expression by neutrophils is not affected substantially by EGCG. Thus, their potential ability to traverse basement membrane barriers and their recruitment at the site of inflammation for immune-surveillance are not likely to be impaired upon treatment with flavanol concentration effective on LE (10-7 M). Indeed, neutrophil motility-proteolysis necessary to transmigrate in vitro through endothelial cell monolayers [38 ] is reduced by EGCG with an IC50 of approximately 10-5 M [39 ].

In addition, thrombin efficiently activates one of the invasion-related gelatinases, MMP-2, as registered in a microvascular endothelial cell model [40 ]. Thrombin is here shown to be inhibited by EGCG at concentrations higher than those effective on MMP-2 [17 , 19 ]; thus, degradation of basement membrane by sprouting endothelial cells during angiogenesis would be restrained primarily by direct inhibition of MMP-2. Conversely, the prevention of cardiovascular pathologies ascribed to green tea consumption [16 ] and the demonstrated antithrombotic activities of catechins [41 ] may not be attributable to direct inhibition of thrombin by EGCG, whose plasma level in green tea drinkers [10 ] reaches 1/200 the IC50 for the proteinase. Even so, the potential use of flavanols as thrombin inhibitors merits deeper investigation.

Furthermore, an IC50 of 8 x 10-8 M has been measured for EGCG on the invasive behavior of tumor cells in vitro [17 , 19 ], over 100-fold lower than that mentioned above for neutrophil transmigration. Whatever lies behind these differences, they offer the possibility of inhibiting disruption of elastic scaffold by LE and tumor-cell aggressiveness, without substantially impairing the physiological traffic of neutrophils, and should certainly facilitate future pharmacological applications of this natural inhibitor.

We conclude that EGCG is a potent inhibitor of LE and an orally available pharmacological agent that may be effective in preventive treatment of individuals exposed to risk of inflammation in general and emphysema in particular, as well as tumor invasion or neoangiogenesis. Regarding the former, the relevance of this conclusion should be confirmed by in vivo experiments; regarding the latter, the role played by LE deserves novel consideration.


    ACKNOWLEDGEMENTS
 
This research was supported by a grant from the "Associazione Italiana per la Ricerca sul Cancro", and a "University of Padova" fellowship, Italy (L. S.). We would like to acknowledge UNIDO-ICS Trieste, for their collaboration. We are grateful to professors M. Spina for helpful discussions and supplying k-elastin; P. Dri (Medical School of Trieste), P. Geppetti (Medical School of Ferrara), G. Lungarella (Medical School of Siena), A. Donella, R. Deana, C. Agostini (Medical School of Padova), and Dr. S. Biggin (UNIDO-ICS, Trieste) for valuable suggestions; and Dr. G. De Silvestro (Immuno-Transfusion Service, Padova Hospital) for supplying buffy-coats.

Received April 1, 2001; revised August 28, 2001; accepted August 29, 2001.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Sternlicht, M. D., Werb, Z. (1999) ECM proteinases Kreis, T. Vale, R. eds. Extracellular Matrix, Anchor, and Adhesion Proteins ,505-509 Oxford University Press Oxford.
  2. Sternlicht, M. D., Werb, Z. (1999) Neutrophil elastase and cathepsin G Kreis, T. Vale, R. eds. Extracellular Matrix, Anchor, and Adhesion Proteins ,543-545 Oxford University Press Oxford.
  3. Rice, W. G., Weiss, S. J. (1990) Regulation of proteolysis at the neutrophil-substrate interface by secretory leukoprotease inhibitor Science 249,178-181[Abstract/Free Full Text]
  4. Liou, T. G., Campbell, E. J. (1996) Quantum proteolysis resulting from release of single granules by human neutrophils: a novel, nonoxidative mechanism of extracellular proteolytic activity J. Immunol. 157,2624-2631[Abstract]
  5. Campbell, E. J., Campbell, M. A., Boukedes, S. S. (2000) Quantum proteolysis by neutrophils. Implications for pulmonary emphysema in {alpha}1-antitrypsin deficiency Chest 117(Suppl. 1),303S[Abstract/Free Full Text]
  6. MacNee, W. (2000) Oxidants/antioxidants and COPD Chest 117(Suppl. 1),303S-317S
  7. Teshima, T., Griffin, J. C., Powers, J. C. (1982) A new class of heterocyclic serine protease inhibitors. Inhibition of human leukocyte elastase, porcine pancreatic elastase, cathepsin G, and bovine chymotrypsin A alpha with substituted benzoxazinones, quinazolines, and anthranilates J. Biol. Chem. 257,5085-5091[Abstract/Free Full Text]
  8. Ranga, V., Kleinerman, J., Ip, M. P. C., Sorensen, J., Powers, J. C. (1981) Effects of oligopeptide chloromethylketone administered after elastase: renal toxicity and lack of prevention of experimental emphysema Am. Rev. Respir. Dis. 124,613-618[Medline]
  9. Yang, C. S., Wang, Z-Y. (1993) Tea and cancer J. Natl. Cancer Inst. 85,1038-1049[Abstract/Free Full Text]
  10. Yang, C. S., Chen, L. S., Lee, M. J., Balentine, D., Kuo, M. C., Schantz, S. P. (1998) Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers Cancer Epidemiol. Biomark. Prev. 7,351-354[Abstract]
  11. Hara, Y. (1997) Prophylactic functions of antioxidants tea polyphenols Ohigashi, K.et al eds. Food Factors for Cancer Prevention Tokyo Japan.
  12. Cao, Y., Cao, R. (1999) Angiogenesis inhibited by drinking tea Nature 398,381[Medline]
  13. Bracke, M., Vyncke, B., Opdenakker, G., Foidart, J. M., De Pestel, G., Mareel, M. (1991) Effect of catechins and citrus flavonoids on invasion in vitro Clin. Exp. Metastasis 9,13-25[Medline]
  14. Taniguchi, S., Fujiki, H., Kobayashi, H., Go, H., Miyado, K., Sadano, H., Shimokawa, R. (1992) Effect of (-)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines Cancer Lett 65,51-54[Medline]
  15. Sazuka, M., Murakami, S., Isemura, M., Satoh, K., Nukiwa, T. (1995) Inhibitory effects of green tea infusion on in vitro invasion and in vivo metastasis of mouse lung carcinoma cells Cancer Lett 98,27-31[Medline]
  16. Nakachi, K., Imai, K., Suga, K. (1997) Epidemiological evidence for prevention of cancer and cardiovascular disease by drinking green tea Ohigashi, K.et al eds. Food Factors for Cancer Prevention Tokyo Japan.
  17. Garbisa, S., Biggin, S., Cavallarin, N., Sartor, L., Benelli, R., Albini, A. (1999) Tumor invasion: molecular shears blunted by green tea Nat. Med. 5,1216[Medline]
  18. Demeule, M., Brossard, M., Page, M., Gingras, D., Beliveau, R. (2000) Matrix metalloproteinase inhibition by green tea catechins Biochim. Biophys. Acta 1478,51-60[Medline]
  19. Garbisa, S., Sartor, L., Biggin, S., Salvato, B., Benelli, R., Albini, A. (2001) Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate Cancer 91,822-832[Medline]
  20. Ohnishi, K., Takagi, M., Kurokawa, Y., Satomi, S., Konttinen, Y. T. (1998) Matrix metalloproteinase-mediated extracellular matrix protein degradation in human polmonary emphysema Lab. Investig. 78,1077-1087[Medline]
  21. Jankun, J., Selman, S. H., Swiercz, R., Skrzypczak-Jankun, E. (1997) Why drinking green tea could prevent cancer Nature 387,561[Medline]
  22. Caenazzo, C., Spina, M., Onisto, M., Fastelli, G., Gotte, L., Agostini, C., Semanzato, G., Garbisa, S. (1990) Degradation of immobilized soluble elastin by tumor cells in culture: quantitation by ELISA Int. J. Cancer 46,552-558[Medline]
  23. Metcalf, J. A., Gallin, J. I., Nauseef, W. M., Root, R. K. (1986) Preparations of cells and materials for functional assays Metcalf, J. A. Gallin, J. I. Nauseef, W. M. Root, R. K. eds. Laboratory Manual of Neutrophil Function ,2-29 Raven New York.
  24. Dri, P., Gasparini, C., Menegazzi, R., Cramer, R., Albèri, L., Presani, G., Garbisa, S., Patriarca, P. (1999) Role of the 75-kDa TNF receptor in TNF-induced activation of neutrophil respiratory burst J. Immunol. 162,460-466[Abstract/Free Full Text]
  25. Schwartz, J. D., Monea, S., Marcus, S. G., Patel, S., Eng, K., Galloway, A. C., Mignatti, P., Shamamian, P. (1998) Soluble factor(s) released from neutrophils activates endothelial cell matrix metalloproteinase-2 J. Surg. Res. 76,79-85[Medline]
  26. Umezawa, H. (1976) Structures and activities of protease inhibitors of microbial origin Methods Enzymol 45,678-695[Medline]
  27. Pacholok, S. G., Davies, P., Dorn, C., Finke, P., Hanlon, W. A., Mumford, R. A., Humes, J. L. (1995) Formation of polymorphonuclear leukocyte elastase:{alpha} 1 proteinase inhibitor complex and A {alpha} (1–21) fibrinopeptide in human blood stimulated with the calcium ionophore A23187 Biochem. Pharmacol. 49,1513-1520[Medline]
  28. Bode, W., Meyer, J. E., Powers, J. C. (1989) Human leukocyte and porcine pancreatic elastase: X-ray crystal structures, mechanism, substrate specificity, and mechanism-based inhibitors Biochemistry 28,1951-1963[Medline]
  29. Gold, A. M. (1967) Sulfonylation with sulfonyl halides Methods Enzymol 11,706-711
  30. Nathan, C. F. (1987) Neutrophyl activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes J. Clin. Investig. 80,1550-1560
  31. Murphy, G., Crabbe, T. (1995) Gelatinase A and B Methods Enzymol 248,470-484[Medline]
  32. Schonbeck, U., Mach, F., Libby, P. (1998) Generation of active IL-1 beta by matrix metalloproteinase: a novel caspase-1-independent pathway of IL-1 beta processing J. Immunol. 161,3340-3346[Abstract/Free Full Text]
  33. Yu, Q., Stamenkovic, I. (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis Genes Dev 14,163-176[Abstract/Free Full Text]
  34. Senior, R. M., Griffin, G. L., Fliszar, C. J., Shapiro, S. D., Goldberg, G. I., Welgus, H. G. (1991) Human 92- and 72-kilodalton type IV collagenases are elastases J. Biol. Chem. 266,7870-7875[Abstract/Free Full Text]
  35. Liu, Z., Zhou, X., Shapiro, S. D., Shipley, J. M., Twining, S. S., Diaz, L. A., Senior, R. M., Werb, Z. (2000) The serpin a1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo Cell 102,647-655[Medline]
  36. Banda, M. J., Rice, A. G., Griffin, G. L., Senior, R. M. (1998) The inhibitory complex of human alpha 1-proteinase inhibitor and human leukocyte elastase is a neutrophil chemoattractant J. Exp. Med. 167,1608-1615[Abstract/Free Full Text]
  37. Pepper, M. S. (2001) Extracellular proteolysis and angiogenesis Thromb. Haemostasis 86,346-355[Medline]
  38. Hofbauer, R. (2000) The Hofbauer-chamber and other modern methods of leukocyte transmigration at the changing millennium Curr. Opin. Clin. Exp. Res. 2,35-45
  39. Hofbauer, R., Frass, M., Gmeiner, B., Handler, S., Speiser, W., Kapiotis, S. (1999) The green tea extract epigallocatechin gallate is able to reduce neutrophil transmigration through monolayers of endothelial cells Wien. Klin. Wochenschr. 111,278-282[Medline]
  40. Nguyen, M., Arkell, J., Jackson, C. J. (1999) Thrombin rapidly and efficiently activates gelatinase A in human microvascular endothelial cells via a mechanism independent of active MT1 matrix metalloproteinase Lab. Investig. 79,467-475[Medline]
  41. Kang, W-S., Lim, I-H., Yuk, D-Y., Chung, K-H., Park, J-B., Yoo, H-S., Yun, Y-P. (1999) Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate Thromb. Res. 96,229-237[Medline]



This article has been cited by other articles:


Home page
J. Immunol.Home page
W. Ding, L. L. Stohl, J. A. Wagner, and R. D. Granstein
Calcitonin Gene-Related Peptide Biases Langerhans Cells toward Th2-Type Immunity
J. Immunol., November 1, 2008; 181(9): 6020 - 6026.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
I. Dell'Aica, R. Niero, F. Piazza, A. Cabrelle, L. Sartor, C. Colalto, E. Brunetta, G. Lorusso, R. Benelli, A. Albini, et al.
Hyperforin Blocks Neutrophil Activation of Matrix Metalloproteinase-9, Motility and Recruitment, and Restrains Inflammation-Triggered Angiogenesis and Lung Fibrosis
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 492 - 500.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
I. Dell'Aica, L. Sartor, P. Galletti, D. Giacomini, A. Quintavalla, F. Calabrese, C. Giacometti, E. Brunetta, F. Piazza, C. Agostini, et al.
Inhibition of Leukocyte Elastase, Polymorphonuclear Chemoinvasion, and Inflammation-Triggered Pulmonary Fibrosis by a 4-Alkyliden-beta-lactam with a Galloyl Moiety
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 539 - 546.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Dona, I. Dell'Aica, E. Pezzato, L. Sartor, F. Calabrese, M. D. Barbera, A. Donella-Deana, G. Appendino, A. Borsarini, R. Caniato, et al.
Hyperforin Inhibits Cancer Invasion and Metastasis
Cancer Res., September 1, 2004; 64(17): 6225 - 6232.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Fassina, R. Vene, M. Morini, S. Minghelli, R. Benelli, D. M. Noonan, and A. Albini
Mechanisms of Inhibition of Tumor Angiogenesis and Vascular Tumor Growth by Epigallocatechin-3-Gallate
Clin. Cancer Res., July 15, 2004; 10(14): 4865 - 4873.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
E. Pezzato, M. Dona, L. Sartor, I. Dell'Aica, R. Benelli, A. Albini, and S. Garbisa
Proteinase-3 directly activates MMP-2 and degrades gelatin and Matrigel; differential inhibition by (-)epigallocatechin-3-gallate
J. Leukoc. Biol., July 1, 2003; 74(1): 88 - 94.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Dona, I. Dell'Aica, F. Calabrese, R. Benelli, M. Morini, A. Albini, and S. Garbisa
Neutrophil Restraint by Green Tea: Inhibition of Inflammation, Associated Angiogenesis, and Pulmonary Fibrosis
J. Immunol., April 15, 2003; 170(8): 4335 - 4341.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sartor, L.
Right arrow Articles by Garbisa, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sartor, L.
Right arrow Articles by Garbisa, S.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS